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correlates with increased overall survival in breast 
cancer, as detected by immunohistochemistry 
using tissue microarray
Elin Möllerström*1, Anikó Kovács2, Kristina Lövgren3, Szilard Nemes4, Ulla Delle1, Anna Danielsson1, Toshima Parris1, 
Donal J Brennan5, Karin Jirström6, Per Karlsson7 and Khalil Helou1
Abstract
Background: Previous studies have shown that the ADIPOR1, ADORA1, BTG2 and CD46 genes differ significantly 
between long-term survivors of breast cancer and deceased patients, both in levels of gene expression and DNA copy 
numbers. The aim of this study was to characterize the expression of the corresponding proteins in breast carcinoma 
and to determine their correlation with clinical outcome.
Methods: Protein expression was evaluated using immunohistochemistry in an independent breast cancer cohort of 
144 samples represented on tissue microarrays. Fisher's exact test was used to analyze the differences in protein 
expression between dead and alive patients. We used Cox-regression multivariate analysis to assess whether the new 
markers predict the survival status of the patients better than the currently used markers.
Results: BTG2 expression was demonstrated in a significantly lower proportion of samples from dead patients 
compared to alive patients, both in overall expression (P = 0.026) and cell membrane specific expression (P = 0.013), 
whereas neither ADIPOR1, ADORA1 nor CD46 showed differential expression in the two survival groups. Furthermore, a 
multivariate analysis showed that a model containing BTG2 expression in combination with HER2 and Ki67 expression 
along with patient age performed better than a model containing the currently used prognostic markers (tumour size, 
nodal status, HER2 expression, hormone receptor status, histological grade, and patient age). Interestingly, BTG2 has 
previously been described as a tumour suppressor gene involved in cell cycle arrest and p53 signalling.
Conclusions: We conclude that high-level BTG2 protein expression correlates with prolonged survival in patients with 
breast carcinoma.
Background
Breast cancer is the most common malignancy among
women, and accounted for approximately 1.15 million
new cases and 411,000 deaths worldwide in 2002 [1].
During the last decade, the survival rate for breast cancer
patients has increased dramatically due to earlier detec-
tion and new treatment protocols [2]. Presently, various
clinical and pathological markers including axillary
lymph node status, hormone receptor status, histological
grade, tumour size, patient age, HER2 expression and
vascular invasion are used to predict breast cancer prog-
nosis and provide accurate treatment [3]. However, these
markers are insufficient and approximately 20 to 30% of
breast cancer patients will die from the disease within five
years of diagnosis [4]. It is, therefore, of great importance
to identify novel molecular markers to further refine
prognosis and response to treatment. Gene expression
analysis has been used to develop gene expression signa-
tures that predict clinical outcome in breast cancer
patients [5-9]. Previously, we analysed breast tumours
from lymph node-negative patients using gene expression
microarray and array-CGH to identify genes with altered
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levels of expression and aberrant chromosomal regions
revealing prognostic values [7,10]. By integrating the
expression and array-CGH results, 27 genes were identi-
fied which differed significantly (P < 0.05) in both gene
expression and DNA copy numbers between deceased
patients and 10-year survivors [10]. Based on their
involvement in breast cancer and the availability of com-
mercial antibodies, the ADIPOR1, ADORA1, BTG2 and
CD46 genes were selected among the 27 previously iden-
tified genes to further investigate the association of pro-
tein expression levels to overall patient survival. In the
present investigation, protein expression was analysed by
immunohistochemistry on tissue microarrays in an inde-
pendent cohort of breast cancer patients, and correlated
to 5-year survival.
Methods
Patients and tissue microarray construction
The breast cancer samples were obtained from 144
patients undergoing surgical resection at Malmö Univer-
sity Hospital, Malmö, Sweden, between 2001 and 2002.
One patient lacked five years follow-up time resulting in
the exclusion of this sample from the 5-year survival anal-
ysis, although not from the multivariate analysis. The 5-
year survival analysis was performed based on overall
survival, including 111 samples from alive and 32 samples
from dead patients. Further clinical information is com-
piled in Table 1. Tissue microarrays (TMAs) containing
duplicate 1.00 mm cores from each tumour were con-
structed as previously described [11]. The utilization of
the tumour material for research purposes was approved
by regional ethical committees in Lund, Sweden.
Immunohistochemistry (IHC)
The expression of ADIPOR1, ADORA1, BTG2 and CD46
proteins was investigated using IHC. Prior to hybridisa-
tion to the tissue microarrays, antibodies corresponding
to the selected genes were optimised on paraffin-embed-
ded sections of breast tumours. After deparaffinisation in
Xylene, the tissue microarrays were autoclaved for at least
one hour in buffer S1699 or S2367 (Dako Norden A/S,
Denmark) or Borgs Decloaker pH9 buffer solution (Bio-
care Medical, CA, USA) (Table 2). The immunohis-
tochemical staining was performed in an automated
immunostainer (TechMate 228 500 Plus; Dako Norden
A/S, Denmark). The TMA sections were incubated with
the different antibodies at a dilution of 1:300 for
ADIPOR1 (Phoenix Pharmaceuticals, Inc, CA, USA),
1:500 for ADORA1 (Genway Biotech, Inc, CA USA),
1:1000 for BTG2 (Genway Biotech, Inc, CA, USA), and
1:40 for CD46 (BD Biosciences, New Jersey, USA); (Table
2). The antibodies were visualised with the EnVision
(K5007, Dako Norden A/S, Denmark) or LSAB (K5001,
D a k o  N o r d e n  A / S ,  D e n m a r k )  v i s u a l i z a t i o n  s y s t e m
according to the manufacturer's instructions (Table 2).
EnVision uses a secondary antibody against both rabbit
and mouse that is directly labelled with HRP (horseradish
peroxidase) reacting with DAB, whereas LSAB uses a sec-
ondary antibody against rabbit and mouse, labelled with
biotin, then streptavidin-HRP is added and the staining is
done with DAB. The TMA sections were then washed in
water, dehydrated in an alcohol gradient followed by
Xylen treatment, and mounted.
Evaluation of IHC
The immunostained tissue microarray sections were
analysed by a pathologist (AK). CD46 protein is a cell
membrane protein, while ADIPOR1 and ADORA1 are
cytoplasm proteins. The subcellular location of BTG2 has
varied in previous publications, and in this study, the
cytoplasm and cell membrane were stained. The cell
membrane staining intensities were graded as no expres-
sion (0), low expression (+), moderate expression (++),
and high expression (+++). The expression of the cyto-
plasm proteins was also graded from 0-3 (ranging from
no expression to high expression). The proportion of
tumour cells expressing membrane and/or cytoplasm
protein was determined. In the evaluation of ADIPOR1,
ADORA1 and CD46, any level of sample staining was
considered positive. For the BTG2 protein, moderate to
strong staining of at least 50% of the cells was required for
the sample to be scored as positive.
Statistical analysis
The difference in expression of the four proteins between
tumours from alive and dead patients was tested using
two-tailed Fisher's exact test. Kaplan-Meier survival
curves were produced using the SPSS version 16 software
to demonstrate the difference in overall survival between
overall BTG2-positive and overall BTG2-negative sam-
ples, as well as BTG2 membrane-positive and BTG2
membrane-negative samples. Significant differences
between the curves were compared using the Breslow-
Wilcoxon test [12]. Additionally, a multivariate analysis
(Cox-regression) was performed to evaluate the clinical
significance of using current prognostic markers (tumour
size, nodal status, HER2 expression, hormone receptor
status, histological grade, and patient age) versus using a
model containing the proposed markers HER2 expres-
sion, patient age, and increasingly used marker Ki67 in
combination with BTG2 expression. To cope with the
reduced validity of the scientific inference due to misrep-
resentation we used Multiple Imputation by Chained
Equations. The effect of the markers on survival probabil-
ity was modelled by Proportional Hazards Model. Vari-
able selection was based on a combination bootstrap and
information theory approach [13]. As an external validat-
ing measure we used time-dependent AUC and Concor-Möllerström et al. BMC Cancer 2010, 10:296
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Table 1: Clinicopathological features of the 144 breast tumour specimens included in this study
deceased patients 5 year survivors lack 5 years follow-up Total
Median age at diagnosis 77 63 75 65
Recurrence free for 5 years
yes 0 102 0 102
no 16 7 1 24
missing 16 2 0 18
Total 32 111 1 144
Type
ductal 26 77 1 104
lobular 4 23 0 27
tubular 1 6 0 7
medullary 1 2 0 3
missing 0 3 0 3
Total 32 111 1 144
Size
median (mm) 27 19 27 20
20 mm and below 11 62 0 73
above 20 mm 21 49 1 71
Total 32 111 1 144
Nodal status
positive 17 38 1 56
negative 10 63 0 73
missing 5 10 0 15
Total 32 111 1 144
Estrogen receptor status
positive 23 101 1 125
negative 9 10 0 19
Total 32 111 1 144
Progesterone receptor status
positive 15 85 0 100
negative 17 26 1 44
Total 32 111 1 144
Her2 status
positive 7 6 0 13
negative 22 101 0 123
missing 3 4 1 8
Total 32 111 1 144Möllerström et al. BMC Cancer 2010, 10:296
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dance index (C-index) [14]. The time-dependent AUC
characterises the temporal changes in predictive accu-
racy. Concordance index offers an easy way to interpret
global accuracy measure that varies between 0.5 and 1. A
concordance index of 1 means that with 100% precision
we can rank the patient's survival time given the recorded
marker information. If the concordance index converges
to 0.5 the ranking of survival times becomes more and
more driven by chance, and becomes completely random
at 0.5. T o quantify the impact of a single marker on the
predictive accuracy we removed one marker at the time
from the final model and refitted a Proportional Hazards
Model and re-estimated the C-index. An estimation of
the correlation between expression of the different pro-
teins were performed using Pearson correlation.
Results
Of the 144 specimens present in the tissue microarray,
136-141 were interpretable for protein expression (Table
3). Excluded samples had few tumour cells, large tissue
loss or affluence of necrotic tissue. BTG2 was expressed
in both the cytoplasm and the cell membrane (Figure 1).
In one sample, BTG2 showed expression in the cytoplasm
and the membrane in one area and was expressed in the
membrane exclusively in another area (Figure 2). The
proportion of BTG2 protein expression was higher in
tumours from 5-year overall survivors than among the
tumours from deceased patients. The overall expression
differed significantly between alive and dead patients (P =
0.026), although there was a stronger association with
membrane specific expression (P  = 0.013) (Table 3).
Kaplan-Meier curves visualize the difference in overall
survival between patients with tumours positive versus
negative for overall and cell membrane specific BTG2
expression in Figure 3. Moreover, the difference between
the curves was significant using the Breslow-Wilcoxon
test [12] for both overall BTG2 (P = 0.011) and cell mem-
brane expression (P  = 0.015). Cytoplasm or cell mem-
brane expression of BTG2 was observed in 78% of the
samples and cell membrane specific expression in 39% of
the samples. None of the remaining three analysed pro-
teins (ADORA1, ADORA1 and CD46) showed a statisti-
cally significant difference in expression between alive
and dead patients in this study (Table 3). The ADIPOR1
protein was expressed in the cytoplasm in 18% of the
samples. The majority of the positive samples showed
primarily granular staining (Figure 4a). Approximately
24% of the samples were positive for ADORA1 staining,
also displaying primarily granular staining in the cyto-
plasm (Figure 4b). Fourteen percent of the samples
expressed CD46 in the cell membrane (Figure 4c).
The multivariate analysis showed that the model con-
taining BTG2 expression had better predictive power
than the model built on current classical pathological
markers (Table 4). The BTG2 model revealed a C-value of
0.781 compared to the slightly lower C-value of 0.772 for
the model of currently used markers. If only the markers
displaying statistical significance are used from the model
of current prognostic markers (HER2 expression and
patient age), a C-value of 0.739 was achieved. Figure 5
shows the classification accuracy of a Cox-regression
model based on the current markers compared to the
classification accuracy of a new model based on the new
markers considered in the present study. Over the whole
time-span considered the new markers offer superior
classification accuracy. For both the new markers and the
old ones the classification accuracy shows a slight
decreasing trend with time. The strongest correlation of
protein expression were between ADIPOR1 and
ADORA1 (k = 0.749) and between BTG2 overall expres-
sion and BTG2 cytoplasm expression (k = 0.723) (Figure
6).
Discussion
In the present investigation, the expression of four pro-
teins (ADIPOR1, ADORA1, BTG2 and CD46) was stud-
ied by IHC using tissue microarrays. The aim was to
evaluate the association between protein expression of
these four genes and 5-year overall survival in breast can-
cer patients. Protein expression of BTG2 was found to be
Table 2: Technical data of the laboratory procedure for each specific antibody
Antibody Antibody 
dilution
Manufacturer Catalogue 
number
Type of 
antibody
Time of 
incubation (RT)
Pre-treatment 
buffer
visualization 
system
AdipoR1 1:300 Phoenix 
Pharmaceuticals
H-001-44 Rabbit 
polyclonal
30 min Borgs decloaker LSAB
Adora1 1:500 Genway Biotech 18-461-10001 Rabbit 
polyclonal
30 min Borgs decloaker LSAB
BTG2 1:1000 Genway Biotech 18-003-42396 Rabbit 
polyclonal
30 min S2367 Envision
CD46 1:40 BD Biosciences 555948 Mouse 
monoclonal
30 min S1699 EnvisionMöllerström et al. BMC Cancer 2010, 10:296
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significantly more prevalent in tumours from alive
patients compared to tumours from dead patients. Fur-
thermore, a multivariate analysis showed that a model
containing BTG2 expression in combination with HER2
expression, patient age and Ki67 expression performed
better, i.e. revealed a higher prediction accuracy, than a
model containing the currently used prognostic markers
(tumour size, nodal status, HER2 expression, hormone
receptor status, histological grade, and patient age). In
this model, BTG2 expression as well as HER2 expression
and patient age were highly significant (P  < 0.0001),
whereas Ki67 expression displayed a lower significance (P
= 0.013). These results further strengthen that BTG2
expression could be a useful complement to the currently
used markers, and in addition, suggest Ki67 expression as
a useful marker of breast cancer survival. This is the first
report of a large quantitative analysis demonstrating that
BTG2 expression is associated with breast cancer patient
survival.
A portion of the samples demonstrated cell membrane
specific expression only, several showed only cytoplasm
expression, and many of the samples showed expression
in both the cell membrane and the cytoplasm (Figure 1).
One sample showed distinct expression of BTG2 in the
cytoplasm and cell membrane in one area and in another
area BTG2 was exclusively expressed in the cell mem-
brane (Figure 2). In previous studies of BTG2, the sub-
cellular location of the protein was diverse. The protein
has been reported to be located in the cytoplasm [15-17]
and in the nucleus [18]. Immunostained lung, kidney and
small intestine tissue display cell membrane expression of
BTG2 in one report [19]. In the present investigation, we
Table 3: Difference in protein expression between tumours from 5-year overall survivors and tumours from deceased 
patients
Dead patients Alive patients
Protein Protein 
expression 
positive (%)
Protein 
expression 
negative (%)
Protein 
expression 
positive (%)
Protein 
expression 
negative (%)
not available (No 
of samples)
P-value dead vs. 
alive patients
A d i p o R 1 2 67 41 78 33 0 . 2 9
Adora1 30 70 23 77 8 0.47
BTG2 61 39 82 18 6 0.026*
-membrane only 19 81 44 56 6 0.013*
-cytoplasm only 52 48 68 32 6 0.14
CD46 16 84 14 86 4 0.77
P-values were calculated using a two-tailed Fisher's exact test. The samples designated as not available had few tumour cells, large tissue loss or 
affluence of necrotic tissue.
Figure 1 Sub-cellular location of the BTG2 protein in this study. Brown colour represents BTG2 staining. BTG2 protein immunohistochemistry 
staining using tissue microarrays show exclusive cell membrane specific expression (A), exclusive cytoplasm expression (B), and both cell membrane 
and cytoplasm expression of BTG2 in the same sample (C).Möllerström et al. BMC Cancer 2010, 10:296
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observed cytoplasm and cell membrane expression, but
no nuclear expression. The various sub-cellular locations
of BTG2 could indicate that the protein is expressed in
different cellular compartments during altering condi-
tions, such as cell cycle phase, differentially expressed in
diverse tissue types, or due to varying specificity of differ-
ent antibodies.
The  BTG2  gene is located at the 1q32 chromosomal
region, which was gained in a significantly higher propor-
tion of 10-year survivors than in deceased lymph node-
negative breast cancer patients in a previous study [10].
The gene belongs to the structurally homogeneous BTG
family of which five genes have been identified in human,
BTG1, BTG2, BTG3, Tob and Tob2. The BTG2 protein is
highly conserved and shares 94% homology with the
m u r i n e  e q u i v a l e n t  [ 2 0 ] .  B T G 2  i s  a  t u m o u r  s u p p r e s s o r
gene [21-23] which is directly regulated by p53 and
involved in p53-mediated response to DNA damage [24].
According to the literature, BTG2 is involved in cell cycle
arrest in the transition from G1 to S phase [25,26]. In
addition, BTG2 can regulate G2 to M cell cycle arrest
independent of p53 [27,28]. BTG2 is known to mediate
chemotherapy induced apoptosis in cancer cells [29-31]
and a study by Lim et al. indicates that BTG2 enhances
cancer cell death by accumulation of H2O2 [32].
Down-regulation of BTG2 has been observed in several
cancer types such as prostate cancer, breast cancer and
gliomas [17,18,33]. In this study 78% of the breast cancer
samples showed moderate to high expression of BTG2 in
the majority of tumour cells. Nevertheless, BTG2 was sig-
nificantly down-regulated in tumours from dead patients
compared to tumours from alive patients, both in overall
expression and cell membrane specific expression. This
finding suggests that high total BTG2 or specific cell
membrane expression may contribute to a prolonged sur-
vival. A previous study analysed BTG2 protein expression
and correlated decreased nucleus expression to a more
aggressive phenotype of breast cancer, although they did
not detect a significant difference in survival [34]. This
discrepancy could be due to the use of different BTG2
Figure 2 Various sub-cellular location of the BTG2 protein in even 
within one sample. One TMA sample showing cytoplasm and cell 
membrane expression of BTG2 in a part of the sample and exclusively 
membranous expression in another part of the sample. Brown colour 
indicates BTG2 staining.
Figure 3 Kaplan-Meier survival curves illustrating the effect of BTG2 expression. The Kaplan-Meier curves show the difference in survival be-
tween patients with tumours that revealed any BTG2 expression and patients whose tumours did not (A), as well as the difference in survival between 
patients with tumours that revealed cell membrane specific BTG2 expression and patients whose tumours did not (B). Solid lines represent patients 
whose tumours expressed BTG2 and dashed lines represent patients whose tumours did not. The p-values for the difference between the curves were 
calculated using a generalized Wilcoxon test.Möllerström et al. BMC Cancer 2010, 10:296
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antibodies since Kawakubo et al. detected staining pre-
dominantly in the nucleus. However, our finding sup-
ports the theory that down-regulation of BTG2
contributes to a more malignant behaviour of the cells.
BTG2 is therefore a promising prognostic marker in
breast cancer.
The proteins ADIPOR1, ADORA1 and CD46 did not
demonstrate differences in expression between tumours
from alive and dead patients. High mRNA levels of
ADIPOR1 have earlier been associated with lower risk of
breast cancer [35]. Previously, Mirza et al. speculated that
increased expression of ADORA1 may contribute to
tumour cell growth and decreased apoptosis in breast
tumour cells [36]. The intensity of CD46 expression has
been negatively correlated with histological grade and
type, tumour size, and tumour recurrence but not to
overall survival [37], which is supported by the results
from this study. These proteins may still be involved in
breast cancer progression, although no significant differ-
ence was seen in expression between alive and dead
Figure 4 Sub-cellular location for samples staining positive for ADIPOR1, ADORA1 and CD46. Brown colour represents staining of the specific 
protein. Immunohistochemistry staining performed for these proteins on tissue microarrays show staining of ADIPOR1 (A) and ADORA1 (B) as granular 
staining in the cytoplasm, and expression of CD46 concentrated to the cell membrane (C).
Table 4: The effect on the survival status of currently used markers compared to BTG2 expression
A Odds Ratio 95%CI P-value C-index
Age 1.058 1.031; 1.087 < 0.0001* 0.711
BTG2 both 0.338 0.336; 0.339 < 0.0001* 0.768
BTG2 cytoplasm 0.699 0.697; 0.700 < 0.0001* 0.768
BTG2 membrane 0.980 0.977; 0.983 < 0.0001* 0.768
HER2 3.331 3.248; 3.416 < 0.0001* 0.768
Ki67 2.441 1.202; 4.956 0.013* 0.758
B Odds Ratio 95%CI P-value C-index
Age 1.058 1.032; 1.085 < 0.0001* 0.696
HER2 2.668 2.640; 2.696 < 0.0001* 0.761
Histological grade 2 0.954 0.294; 3.094 0.938 0.770
Histological grade 3 1.463 0.432; 4.949 0.539 0.770
Hormone receptor 
status
0.567 0.248; 1.296 0.179 0.767
Nodal Status 1.673 0.823; 3.398 0.154 0.768
Tumour size 1.569 0.739; 3.330 0.240 0.765
A Cox-regression multivariate analysis was performed to test the effect on survival status of the markers used in current clinical praxis and 
the changes in the model predictive power induced by the removal of a single marker. The predictive power of the full new model as 
measured by the C-index is 0.781 (A). The C-index for the old model is 0.772 (B), and the model with only the statistically significant variables 
in the old model has a predictive power of 0.739.Möllerström et al. BMC Cancer 2010, 10:296
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patients in the current investigation. The strongest corre-
lations in protein expression were between ADIPOR1
and ADORA1, as well as BT G2 overall expression and
BTG2 cytoplasm expression. The BTG2 correlation was
expected since BTG2 overall expression is a combination
of BTG2 cytoplasm expression and BTG2 membrane spe-
cific expression. The correlation between ADIPOR1 and
ADORA1 is however difficult to explain since they to our
knowledge do not interact, although both were expressed
in similar proportions of the samples in this study (Table
3), and they are located at 1q32, within 300 000 base pairs
from each other. This correlation might be interesting for
further investigation.
Conclusions
We conclude that high BTG2 expression levels correlate
with prolonged breast cancer survival. Furthermore,
BTG2 protein expression may be used as a prognosticator
for breast cancer as well as a possible molecular target in
breast cancer treatment. Further studies in independent
Figure 5 Variation of the predictive power depending on survival time. The new Cox-regression model containing BTG2 expression, HER2 ex-
pression, patient age and Ki67 expression performed better, i.e. revealed higher prediction accuracy, than a Cox-regression model containing the cur-
rently used prognostic markers that gained statistical significance (HER2 expression, and patient age). This difference in predictive power was stable, 
independent of survival time.Möllerström et al. BMC Cancer 2010, 10:296
http://www.biomedcentral.com/1471-2407/10/296
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tumour sets are needed to validate and establish BTG2
protein expression as a prognostic marker.
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